Our results tend to support these overall findings of reliable remodelling of DBM to new bone. The histological analysis showed significant new bone formation and decreasing residual DBM material in ...
As previously disclosed, in late Q3 2022, the Company began to experience material supply issues related to its ALLOCYTE ® Advanced Cellular Bone Matrix (“ALLOCYTE”) product line. The supply ...
SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health announced today that the first patient has been treated with its newly released OssiGraft™ viable bone matrix (VBM) allograft in an ankle surgery, ...
MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of ...
SAN FRANCISCO & PARSIPPANY, N.J.--(BUSINESS WIRE)--Ossium Health®, a bioengineering company that established a first-of-its-kind bone marrow banking platform, has entered into a collaborative ...
Molecular Matrix, a privately held company that arose from the University of California, Davis, received FDA approval for its Osteo-P bone graft substitute technology. Osteo-P is a non-mineralized, ...
Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus
Sean Browne, President and CEO of Xtant Medical, stated, "New product launches are a key component of our strategy to drive margin improvement on higher sales and generate positive operating cash flow ...
Nine patients (6 male and 3 female, 30 to 64 years old) that were scheduled for elective removal of dorsal instrumentation hardware over a 12-month time period were included in our study. Indications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback